Publications
214
Citations
4,471
Est. group size
~2
Recurring co-author estimate
Active years
24
Publishing since 2003
Adrian L. Oblak studies Alzheimer's disease and related dementias, using genetically engineered mouse models to understand how brain immune cells (microglia), inflammation, and genetic risk factors like APOE contribute to amyloid plaques and tau pathology. The work also includes preclinical drug testing platforms for Alzheimer's and extends to related areas such as cancer biology, obesity drug models, and neuroinflammation. A recurring focus is translating findings from animal models toward potential treatments.
Publication activity has been high and steady over the last several years, averaging around 20 papers per year (recent 2025-2026 counts appear lower likely due to incomplete indexing).
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Current awards run through March 2030 — about 4 years of funding on record from today. Awards are often renewed, so this is what is currently public, not a forecast.
siRNA-mediated Knockdown of INPP5D to Modulate Microglia Activity for the Treatment of Alzheimer's Disease
Optimization of SHIP1 Inhibitors for the Treatment of Alzheimer's Disease
IU/JAX/PITT MODEL-AD Center
The Role of Peripheral Immune Cell Trafficking in Ozone-Induced Alzheimer's Disease Neuropathology
The Role of Aspergillus versicolor and the Th2 Lung-Brain Axis in Alzheimer's Disease-like Neuropathology
2 earlier awards
- NIH RF1AG077826Jun 2022 – May 2025 · $1.7M awarded
The Role of Peripheral Immune Cell Trafficking in Ozone-Induced Alzheimer's Disease Neuropathology
- NIH K01AG054753Sep 2017 – May 2023 · $125k awarded
In vivo assessment of the role of neurons and glia in tau propagation
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~9 · 7% small-team papers (≤3 authors) · across 31 venues
- APOE4 Increases Systemic Inflammation and Alters Metabolic and Neuroprotective Pathways following Multiagent Chemotherapy in Older Human APOE Knock-In Mice
American Journal Of Pathology · 2026
- Detecting Beta-Amyloid Plaque via Low Rank Based Orthogonal Projection and Spatial-Spectrum Detector Using High-Resolution Quantitative Susceptibility Mapping for Preclinical Studies
IEEE Transactions on Biomedical Engineering · 2025
- Animal models for development of anti-obesity drugs in the age of GLP-1 agents
Expert Opinion on Drug Discovery · 2025
- Molecular and Synaptic Signatures in Mouse Models of Late‐Onset Alzheimer’s Disease Independent of Amyloid and Tau Pathology
Alzheimer s & Dementia · 2024
- Peripheral HMGB1 is linked to O3 pathology of disease‐associated astrocytes and amyloid
Alzheimer s & Dementia · 2024
- Gene replacement‐Alzheimer's disease (GR‐AD): Modeling the genetics of human dementias in mice
Alzheimer s & Dementia · 2024
- Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine
JCI Insight · 2024
- Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+ breast cancer
Cell chemical biology · 2024
- Mapping the Anti-Cancer Activity of α-Connexin Carboxyl-Terminal (aCT1) Peptide in Resistant HER2+ Breast Cancer
Cancers · 2024
- HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer
OncoImmunology · 2024
- Deciphering Microglial Contributions to Amyloid and Tau Pathology in Diverse Genetic Contexts
Alzheimer s & Dementia · 2024
- Effects of binge alcohol administration on tauopathy and neuroinflammation in PS19 mice
Alzheimer s & Dementia · 2023
- IL-34 exacerbates pathogenic features of Alzheimer’s disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice
Biomedicine & Pharmacotherapy · 2023
- INPP5D inhibition attenuates amyloid pathology through the regulation of microglial functions
Alzheimer s & Dementia · 2023
- STOP‐AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's disease
Alzheimer s & Dementia · 2023
- Alzheimer s & Dementia×72
- bioRxiv (Cold Spring Harbor Laboratory)×15
- PMC×7
- Figshare×6
- Alzheimer s & Dementia Translational Research & Clinical Interventions×5
- Donna M. Wilcock
Medicine · Indiana University
- Paul R. Territo
Medicine · Indiana University
- Oscar Harari
Medicine · The Ohio State University
- Bruce T. Lamb
Medicine · Indiana University
- Diana Acosta
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile